{"id":"azithromycin-ivermectin-ribaroxaban-paracetamol","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (azithromycin)"},{"rate":null,"effect":"Pruritus and rash (ivermectin)"},{"rate":null,"effect":"Bleeding (rivaroxaban)"},{"rate":null,"effect":"Hepatotoxicity (paracetamol)"}]},"_chembl":{"chemblId":"CHEMBL6067487","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin is a macrolide antibiotic that binds to bacterial 50S ribosomal subunits. Ivermectin is an antiparasitic that enhances GABA-mediated chloride channel opening in parasites. Rivaroxaban is a direct factor Xa inhibitor that prevents thrombin generation. Paracetamol inhibits prostaglandin synthesis in the CNS. This unusual combination suggests either a compounded formulation or a non-standard investigational product.","oneSentence":"This is a fixed-dose combination of four active ingredients with distinct mechanisms: azithromycin inhibits bacterial protein synthesis, ivermectin paralyzes parasites, rivaroxaban inhibits factor Xa in the coagulation cascade, and paracetamol reduces pain and fever through central nervous system effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:26.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown — this combination is highly unusual and not a recognized marketed or standard pipeline product"}]},"trialDetails":[{"nctId":"NCT04673214","phase":"PHASE3","title":"Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","status":"COMPLETED","sponsor":"Gilberto Cruz Arteaga","startDate":"2020-12-16","conditions":"Covid19","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["with Ivermectin"],"phase":"phase_3","status":"active","brandName":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","genericName":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","companyName":"Gilberto Cruz Arteaga","companyId":"gilberto-cruz-arteaga","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of four active ingredients with distinct mechanisms: azithromycin inhibits bacterial protein synthesis, ivermectin paralyzes parasites, rivaroxaban inhibits factor Xa in the coagulation cascade, and paracetamol reduces pain and fever through central nervous system effects. Used for Unknown — this combination is highly unusual and not a recognized marketed or standard pipeline product.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}